Literature DB >> 18329347

Differential liquid phase proteomic analysis of the effect of selenium supplementation in LNCaP cells.

Antonella Roveri1, Maria Pia Vitale, Elena Serain, Mattia Zaccarin, Pierluigi Mauri, Dario Di Silvestre, Antonella De Palma, Massimo Gion, Stefano Toppo, Matilde Maiorino, Fulvio Ursini.   

Abstract

The effect of 100 nM sodium selenite supplementation was studied on LNCaP cells by a proteomic approach, on ProteomeLab PF 2D platform. Proteins were separated by liquid phase bi-dimensional chromatography and analyzed by pair-wise alignment of peaks to detect those differentially expressed. Differential expression threshold was set at a twice difference level and proteins matching this criterion were identified by MALDI-TOF and confirmed by ESI-ion trap MS/MS. Not all differentially expressed proteins found by PF 2D could be identified by MS analysis, the sensitivity of which emerging as the limiting factor. Thus, only the most abundant proteins, differently expressed following selenium supplementation, were identified. We positively showed an increase of expression of thioredoxin reductase 1, enolase 1, phosphoglycerate mutase 1, glyceraldehyde-3-phosphate dehydrogenase, heterogeneous nuclear ribonucleoprotein A2/B1, isoform A2, Ras-GTPase-activating protein SH3-domain-binding protein and Keratin 18 and a decrease of expression of peroxiredoxin 1 and heat shock protein 70, protein 8, isoform 1. Results are consistent, at least in part, with the less oxidant environment brought about by the synthesis of Se-dependent peroxidases, keeping low the steady-state concentration of hydrogen peroxide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329347     DOI: 10.1016/j.jchromb.2008.02.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  1 in total

Review 1.  Potential stages for prostate cancer prevention with selenium: implications for cancer survivors.

Authors:  Nicole Facompre; Karam El-Bayoumy
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.